Swiss Biotech Windward Raises $225 Million in US IPO, Placement
THE SO WHAT
Windward Bio pulling in ~$225M in a US IPO shows public markets are still open to non-AI biotech with a credible pipeline. For founders in regulated deep tech, this is a data point that crossover and public capital are available if you can articulate near-term clinical or regulatory milestones.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureJensen Huang’s departure blasts big hole in AI startup funding, VCs and founders say
Nvidia under Huang was effectively a mega-fund for AI startups — tens of billions in checks and hardware credits that set valuation floors. With that spigot uncertain, founders should assume longer fundraising cycles, more structured deals, and less “strategic premium” baked into rounds.
Startups & VentureSources: Moonshot AI is deactivating its Cayman holding company and moving investors' stakes to its primary operating entity in China to pave the way for an IPO
Collapsing the Cayman holdco into the onshore China opco to prep an IPO is a signal that top-tier Chinese AI companies are willing to trade offshore flexibility for domestic capital access. If you’re exposed to China AI — as a partner, investor, or competitor — assume more listings onshore and less insulation from Chinese regulatory reach.
Startups & VentureBitcoin could fall even further if investors cash out to buy into the Anthropic IPO
The Anthropic IPO is big enough that some funds may rotate out of liquid risk assets like Bitcoin to make room. If you’re exposed to both, treat this as a correlated-liquidity event, not two independent bets.
Startups & VentureAnthropic IPO Buyers Have More Influence on Price Than SpaceX
A bookbuild where major investors have outsized sway on Anthropic’s initial price means this IPO is a negotiated macro bet on AI, not just a growth story. If you’re a later-stage private AI company, expect your own valuation conversations to anchor on how disciplined this pricing looks in hindsight.